Sir, A large number of acquired carbapenemases have been identified and characterized among Gram-negative pathogens. These diverse enzymes, belonging to either molecular classes A and D (serine carbapenemases and oxacillinases) or molecular class B [metallo-b-lactamases (MBLs)], have emerged on a global scale and represent serious public health challenges, compromising therapeutic choices and complicating patient management. 1 -3 Genes encoding carbapenemases are associated with mobile genetic elements that allow rapid dissemination in the clinical setting. Therefore, detection and surveillance of carbapenemaseproducing organisms have become matters of major importance for the selection of appropriate therapeutic schemes and the implementation of infection control measures. 1, 3 In this study, we analysed the rates of carbapenem resistance and carbapenemase production among a total of 15948 isolates of Escherichia coli (n¼10 432) and Klebsiella spp. (n¼5516) consecutively collected during 2007-09, which were evaluated as part of the SENTRY antimicrobial surveillance programme.
E. coli and Klebsiella spp. were sampled from 83 medical centres located in the USA, Europe and Latin America (30, 10 and 43 institutions, respectively). These consecutive non-duplicate isolates were cultured from bloodstream, respiratory tract, and skin and skin structure infections. Isolates were tested for antimicrobial susceptibility using the 2009 CLSI broth microdilution method 4 and results were interpreted according to the M100-S20-U document (CLSI, 2010).
5 E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were concurrently tested for quality assurance; all results were in the CLSI published range. Overall, resistance to imipenem and/or meropenem (MIC values ≥2 mg/L) was observed among 2.0% (323/15 948) of the E. coli (n¼ 29) and Klebsiella spp. (n¼ 294; 281 Klebsiella pneumoniae and 13 Klebsiella oxytoca) isolates (Table 1 ). All 323 isolates resistant to imipenem or meropenem were tested with the modified Hodge test (MHT) 6 using imipenem and meropenem discs, and were also screened for the presence of bla IMP , bla VIM , bla KPC, bla SME and bla GES variants as well as for bla IMI , bla NMC-A and bla OXA-48 by multiplex PCRs using custom primers (Table S1 , available as Supplementary data at JAC Online). The gene encoding NDM-1 was tested in a separate reaction. Amplicons were sequenced on both strands. Carbapenem resistance and carbapenemase production rates among different groups were compared using the x 2 test. P values ,0.05 were considered to be significant. The rates of carbapenem resistance and carbapenemase production among Klebsiella spp. were higher than those seen among E. coli. Overall, only 29 (0.3%) E. coli strains demonstrated elevated carbapenem MIC values and 16 (0.2%) were carbapenemase producers, whereas among Klebsiella spp. carbapenem resistance and carbapenemase production were 5.3% and 3.8%, respectively (Table 1) .
Carbapenem resistance rates for all regions combined were stable through the years, varying from 1.8% to 2.4% in 2007 and 2009, respectively {P¼0.0467; odds ratio (OR) 0.76 [95% confidence interval (CI) 0.58-1.01]; Table 1} . Carbapenemase production, detected by MHT and PCR, was observed among 228 (1.4%) isolates and analyses by year demonstrated an increasing trend toward carbapenemase production. In the first 2 years, carbapenemase production was 1.2% (2007) Only five strains (all K. pneumoniae) showed repeatedly discrepant results between MHT and PCR. One bla OXA-48 -and one bla KPC-2 -carrying strain were negative for MHT. Three strains (one from Turkey and two from the USA) were positive for MHT and negative for PCR.
Carbapenemase production significantly increased in this systematic evaluation of a contemporary worldwide E. coli and Klebsiella spp. collection, whereas MBL rates were stable over the study period or associated with local epidemic, clonal occurrences. The dissemination of KPC-producing isolates in all geographical regions and of OXA-48 in Turkish hospitals contributed directly to the described escalating resistance trends.
Carbapenemase production cannot be inferred from the antimicrobial resistance profile; thus, the dissemination of these enzymes must be closely monitored [molecular and/or phenotypic tests (MHT)] and strategies implemented, as effective surveillance initiatives. Carbapenem resistance was as defined by CLSI document M100-S20-U. 
